Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 57, Issue 3, 2008, Pages 380-386

  Hogue, Jean Charles ^a   Lamarche, Benoît ^a   Tremblay, André J ^a   Bergeron, Jean ^a   Gagné, Claude ^a   Couture, Patrick ^a  

^a UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; BIOLOGICAL MARKER; CELL ADHESION MOLECULE; FENOFIBRATE; LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG EFFECT; FEMALE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ANTILIPEMIC AGENTS; BIOLOGICAL MARKERS; CELL ADHESION MOLECULES; DIABETES MELLITUS, TYPE 2; FEMALE; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTRIGLYCERIDEMIA; INFLAMMATION; LIPIDS; LIPOPROTEINS; LIPOPROTEINS, LDL; MALE; MIDDLE AGED; OXIDATION-REDUCTION; PROCETOFEN; PYRROLES;

EID: 38749088004     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2007.10.014     Document Type: Article

References (33)

1. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
2. Verma S., and Anderson T.J. Fundamentals of endothelial function for the clinical cardiologist. Circulation 105 (2002) 546-549
3. Lowe G.D., and Pepys M.B. C-reactive protein and cardiovascular disease: weighing the evidence. Curr Atheroscler Rep 8 (2006) 421-428
4. Zwaka T.P., Hombach V., and Torzewski J. C-reactive protein-mediated low density lipoprotein uptake by macrophages: implications for atherosclerosis. Circulation 103 (2001) 1194-1197
5. Constans J., and Conri C. Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta 368 (2006) 33-47
6. Steinberg D. Low density lipoprotein oxidation and its pathobiological significance. J Biol Chem 272 (1997) 20963-20966
7. Mezzetti A., Cipollone F., and Cuccurullo F. Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. Cardiovasc Res 47 (2000) 475-488
8. Galis Z.S., and Khatri J.J. Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res 90 (2002) 251-262
9. Marx N., Froehlich J., Siam L., et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 23 (2003) 283-288
10. Kougias P., Chai H., Lin P.H., et al. Lysophosphatidylcholine and secretory phospholipase A2 in vascular disease: mediators of endothelial dysfunction and atherosclerosis. Med Sci Monit 12 (2006) RA5-RA16
11. Ginsberg H.N. Insulin resistance and cardiovascular disease. J Clin Invest 106 (2000) 453-458
12. Staels B., Dallongeville J., Auwerx J., et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation 98 (1998) 2088-2093
13. Jones P., Kafonek S., Laurora I., et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81 (1998) 582-587
14. Davignon J., and Laaksonen R. Low-density lipoprotein-independent effects of statins. Curr Opin Lipidol 10 (1999) 543-559
15. Pyorala K., Pedersen T.R., Kjekshus J., et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care 20 (1997) 614-620
16. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
17. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360 (2002) 7-22
18. Report of the Expert Committee on the Diagnosis and classification of diabetes mellitus. Diabetes Care 27 Suppl 1 (2004) S5-S10
19. Jialal I., Stein D., Balis D., et al. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 103 (2001) 1933-1935
20. Kleinveld H.A., Demacker P.N., De Haan A.F., et al. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors. Eur J Clin Invest 23 (1993) 289-295
21. Bredie S.J., de Bruin T.W., Demacker P.N., et al. Comparison of gemfibrozil versus simvastatin in familial combined hyperlipidemia and effects on apolipoprotein-B-containing lipoproteins, low-density lipoprotein subfraction profile, and low-density lipoprotein oxidizability. Am J Cardiol 75 (1995) 348-353
22. Oranje W.A., Sels J.P., Rondas-Colbers G.J., et al. Effect of atorvastatin on LDL oxidation and antioxidants in normocholesterolemic type 2 diabetic patients. Clin Chim Acta 311 (2001) 91-94
23. Pietsch A., Erl W., and Lorenz R.L. Lovastatin reduces expression of the combined adhesion and scavenger receptor CD36 in human monocytic cells. Biochem Pharmacol 52 (1996) 433-439
24. Strandberg T.E., Vanhanen H., and Tikkanen M.J. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 353 (1999) 118-119
25. Bellosta S., Via D., and Canavesi M. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol 18 (1998) 1671-1678
26. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 24 (2006) 33-50
27. Marx N., Duez H., Fruchart J.C., et al. Peroxisome proliferators-activated receptors and atherogenesis: regulators of gene expression in vascular cells. Circ Res 94 (2004) 1168-1178
28. Calabresi L., Gomaraschi M., Villa B., et al. Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol. Arterioscler Thromb Vasc Biol 22 (2002) 656-661
29. Empen K., Frost R.J., Geiss H.C., et al. Differential effects of fenofibrate versus atorvastatin on the concentrations of E-selectin and vascular cellular adhesion molecule-1 in patients with type 2 diabetes mellitus and mixed hyperlipoproteinemia: a randomized cross-over trial. Cardiovasc Diabetol 2 (2003) 17
30. Kowalski J., Okopien B., Madej A., et al. Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia. Int J Clin Pharmacol Ther 41 (2003) 241-247
31. Robbesyn F., Salvayre R., and Negre-Salvayre A. Dual role of oxidized LDL on the NF-kappaB signaling pathway. Free Radic Res 38 (2004) 541-551
32. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
33. Devaraj S., Chan E., and Jialal I. Direct demonstration of an anti-inflammatory effect of simvastatin in subjects with the metabolic syndrome. J Clin Endocrinol Metab 91 (2006) 4489-4496